Robert Califf’s quest for increased oversight and monitoring of the medical product supply chain sounds like an old generic industry idea intended to help avert drug shortages.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?